Literature DB >> 25714006

Identification of rictor as a novel substrate of Polo-like kinase 1.

Tian Shao1, Xiaoqi Liu.   

Abstract

Plk1 has been essentially described as a critical regulator of many mitotic events. However, increasing evidence supports the notion that its molecular functions are not restricted to the cell cycle. In particular, recent reports suggest the existence of a molecular and functional link between Plk1 and the mammalian target of rapamycin (mTOR) pathway, which controls cell growth and proliferation via the raptor-mTOR (TORC1) and rictor-mTOR (TORC2) protein complexes. Herein, we have identified rapamycin-insensitive companion of mTOR (Rictor), a core component of mTORC2, as a new Plk1 substrate and have shown that Plk1 phosphorylates Rictor at Ser1162 in vitro and in vivo. Surprisingly, cells expressing the unphosphorylatable mutant (S1162A) of Rictor did not show any effect on well characterized canonical PI3K-mTOR pathway. However, we found that cells expressing the unphosphorylatable form of Rictor have an elevated level of mSin1 isoform (mSin1.5). Considering that mSin1.5-containing mTORC2 was reported to associate with stress signaling, we propose that phosphorylation of Rictor at Ser1162 by Plk1 might be involved in a novel signaling pathway by regulating the mSin1.5-defined mTORC2.

Entities:  

Keywords:  4E-BP1, eIF4E-binding protein 1; GST, glutathione S-transferase; IB, immunoblotting.; IP, immunoprecipitation; PDK1, 3-phophoinositide-dependent protein kinase 1 (PDK1); Plk1; Plk1, polo-like kinase 1; Raptor, regulatory-associated protein of mTOR; Rictor; Rictor, rapamycin-insensitive companion of mTOR; S6K, S6 Kinase; WT, wild type; aa, amino acids; cell cycle; mSin1; mSin1, mammalian stress-activated map kinase-interacting protein 1 (mSin1); mTOR, mammalian target of rapamycin; mTORC; mTORC1, mTOR complex 1; mTORC2, mTOR complex 2; phosphorylation

Mesh:

Substances:

Year:  2015        PMID: 25714006      PMCID: PMC4615041          DOI: 10.1080/15384101.2014.998050

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  35 in total

1.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

Review 2.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

3.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control.

Authors:  Robbie Loewith; Estela Jacinto; Stephan Wullschleger; Anja Lorberg; José L Crespo; Débora Bonenfant; Wolfgang Oppliger; Paul Jenoe; Michael N Hall
Journal:  Mol Cell       Date:  2002-09       Impact factor: 17.970

4.  Normal cells, but not cancer cells, survive severe Plk1 depletion.

Authors:  Xiaoqi Liu; Ming Lei; Raymond L Erikson
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

Review 5.  mTOR: from growth signal integration to cancer, diabetes and ageing.

Authors:  Roberto Zoncu; Alejo Efeyan; David M Sabatini
Journal:  Nat Rev Mol Cell Biol       Date:  2010-12-15       Impact factor: 94.444

6.  Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells.

Authors:  Xiaoqi Liu; Raymond L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

7.  Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

Authors:  D D Sarbassov; Siraj M Ali; Do-Hyung Kim; David A Guertin; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Curr Biol       Date:  2004-07-27       Impact factor: 10.834

8.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive.

Authors:  Estela Jacinto; Robbie Loewith; Anja Schmidt; Shuo Lin; Markus A Rüegg; Alan Hall; Michael N Hall
Journal:  Nat Cell Biol       Date:  2004-10-03       Impact factor: 28.824

Review 9.  Targeting polo-like kinase 1 for cancer therapy.

Authors:  Klaus Strebhardt; Axel Ullrich
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

10.  Relocation of Aurora B from centromeres to the central spindle at the metaphase to anaphase transition requires MKlp2.

Authors:  Ulrike Gruneberg; Rüdiger Neef; Reiko Honda; Erich A Nigg; Francis A Barr
Journal:  J Cell Biol       Date:  2004-07-19       Impact factor: 10.539

View more
  4 in total

1.  Plk1 phosphorylation of Numb leads to impaired DNA damage response.

Authors:  C Shao; S-J Chien; E Farah; Z Li; N Ahmad; X Liu
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

Review 2.  Regulatory functional territory of PLK-1 and their substrates beyond mitosis.

Authors:  Shiv Kumar; Garima Sharma; Chiranjib Chakraborty; Ashish Ranjan Sharma; Jaebong Kim
Journal:  Oncotarget       Date:  2017-06-06

3.  PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy.

Authors:  Stefanie Ruf; Alexander Martin Heberle; Miriam Langelaar-Makkinje; Sara Gelino; Deepti Wilkinson; Carolin Gerbeth; Jennifer Jasmin Schwarz; Birgit Holzwarth; Bettina Warscheid; Chris Meisinger; Marcel A T M van Vugt; Ralf Baumeister; Malene Hansen; Kathrin Thedieck
Journal:  Autophagy       Date:  2017-01-19       Impact factor: 16.016

4.  Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.

Authors:  Andreas Ritter; Alexandra Friemel; Nina-Naomi Kreis; Frank Louwen; Juping Yuan
Journal:  Oncotarget       Date:  2016-12-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.